Many innovators lament that the time-honored VC model does not work for what they call “cleantech” or “greentech.” They raise as proof the capital intensivity and long timeframes for energy start-ups. I say they have it backwards. Energy will get solved when the energy ecology changes to fit the VC model, not vice versa. Take … Continue reading “Blue Is the New Green: Why Energy Entrepreneurs Need to Think Different”
Category: National
Scandal, Swine Flu, Shareholder Disputes, and More: 2009 Was Quite a Year for San Diego’s Life Sciences Industry
Covering the life sciences in San Diego is never dull, and the news flow last year provided plenty of drama. What follows are some highlights from the past year: — Embattled tools company Sequenom (NASDAQ: [[ticker:SQNM]]) scuttled the debut of a non-invasive prenatal Down syndrome test amid a data-mishandling scandal. CEO Harry Stylli was fired … Continue reading “Scandal, Swine Flu, Shareholder Disputes, and More: 2009 Was Quite a Year for San Diego’s Life Sciences Industry”
VLST Cuts Jobs To Preserve Cash, Still Feeding Novo Nordisk Pipeline
VLST, the Seattle-based biotech company seeking new ways of treating autoimmune diseases, has recently completed a round of layoffs. I received a tip that the company eliminated about 30 percent of its workforce in recent weeks. CEO Marty Simonetti confirmed that job cuts have occurred, but wouldn’t say how many people were let go or … Continue reading “VLST Cuts Jobs To Preserve Cash, Still Feeding Novo Nordisk Pipeline”
Metaplace Pulling Plug on Website
San Diego-based Metaplace co-founder Ralph Koster announced on his blog today that the venture-backed company is shutting down Metaplace.com, its user-generated content website, effective Jan. 1. Koster, the former chief creative officer at Sony Online, says the Metaplace website, which offers users an online marketplace and platform for building their own social networking rooms “just … Continue reading “Metaplace Pulling Plug on Website”
MIT Media Lab Director Aims to Transform Healthcare—By Bringing Patients Front and Center
An avalanche of new technology promises to transform healthcare. You’ve heard a lot about it: Electronic medical records. New ways to mine genomic data to match patients with the right medicines. Everything from iPhone apps and robots to help you exercise or take your meds. Not to mention relatively “old” advances like digital imaging and … Continue reading “MIT Media Lab Director Aims to Transform Healthcare—By Bringing Patients Front and Center”
My Top 10 List of Innovations Across the Spectrum
Here are my top 10 innovations that are coming to the forefront in 2010. Of course, none of these would be possible without the economic engine that is embodied by the USA Science & Engineering Festival, which is creating the innovative minds of the future. 1) High-tech treatment of nuclear waste, a technology that solves … Continue reading “My Top 10 List of Innovations Across the Spectrum”
EyeGate Pharma, Delivering Drugs Into the Eye, Raises $11M Out of $23M Round
EyeGate Pharma, a Waltham, MA-based company developing more effective ways to deliver drugs into the eye, has raised $11 million in new financing out of an equity round that could potentially bring in $22.7 million, according to a regulatory filing today. EyeGate hasn’t issued a statement on the financing, and a company spokesman couldn’t immediately … Continue reading “EyeGate Pharma, Delivering Drugs Into the Eye, Raises $11M Out of $23M Round”
ZymoGenetics Regains Full U.S. Rights to Recothrom as Bayer Walks Away
If ZymoGenetics is going to make its lone marketed product into a success, it will have to do it on its own. The Seattle-based biotech company said today that its partner, Germany-based Bayer, is walking away from its U.S. commercial rights to the drug for surgical bleeding. ZymoGenetics (NASDAQ: [[ticker:ZGEN]]) said today it is getting … Continue reading “ZymoGenetics Regains Full U.S. Rights to Recothrom as Bayer Walks Away”
Qualcomm Plans to Repeat Global QPrize, With a Few Changes
After reporting reporting last month that Israeli startup Panoramic Power won the inaugural QPrize, the incentive prize organized by Qualcomm Ventures, I recently got a chance to discuss the outcome with Nagraj Kashyap, vice president of Qualcomm Ventures. He says the San Diego wireless industry giant intends to organize a second round of its business … Continue reading “Qualcomm Plans to Repeat Global QPrize, With a Few Changes”
The New Google: Internet Giant Opens Up About Real-Time and Local Search, Cloud Computing, and Data Liberation
When it comes to product and business strategy, Google is one of the most secretive companies around. So I was pleased when the Internet giant agreed to grant me a series of interviews last week, most of them with senior product managers from its Mountain View, CA, headquarters. I touched on elements of Google’s technology … Continue reading “The New Google: Internet Giant Opens Up About Real-Time and Local Search, Cloud Computing, and Data Liberation”
OncoGenex Grabs $60M Upfront From Teva for Rights to Cancer Drug, Shares Drop Anyway
[Updated: 12:30 pm Eastern time 12/21/09, with stock reaction.] The Cinderella story of Seattle biotech in 2009 is making more news. Bothell, WA-based OncoGenex Pharmaceuticals (NASDAQ: [[ticker:OGXI]]) is announcing today it has clinched $60 million in upfront payments from Israel-based Teva Pharmaceutical for the right to co-develop an experimental prostate cancer drug that has been … Continue reading “OncoGenex Grabs $60M Upfront From Teva for Rights to Cancer Drug, Shares Drop Anyway”
Agios, Seeking to Starve Cancer Cells to Death, Wins Support from Brain Tumor Foundation
Cancer cells can essentially get addicted to food, and Agios Pharmaceuticals thinks it has a groundbreaking way to starve them to death. Now it’s getting some help to test the idea from a foundation started by the family of AOL founder Steve Case. The Cambridge, MA-based biotech company is announcing today that it has secured … Continue reading “Agios, Seeking to Starve Cancer Cells to Death, Wins Support from Brain Tumor Foundation”
Qualcomm’s Top Executives Talk Shop, Verari Lays Off Nearly Everyone, Assay Depot Goes From Biotech Startup to Online Merchant, & More San Diego BizTech News
San Diego’s tech news slowed to a trickle last week, as considerable speculation focused on the restructuring at Verari Systems, which included laying off most of the data equipment supplier’s workforce. Keep reading to get the latest news. —San Diego-based Verari Systems abruptly laid off most of its employees, prompting a flurry of reports that … Continue reading “Qualcomm’s Top Executives Talk Shop, Verari Lays Off Nearly Everyone, Assay Depot Goes From Biotech Startup to Online Merchant, & More San Diego BizTech News”
India’s Innovation Front Lines 2009 (Part 1): Of “Jugaar” and A Quick Recovery from Global Recession
Driving from Delhi to Jaipur on the Delhi-Jaipur highway, December 17, 2009—The new 10-lane Gurgaon highway, opened a year back, is already at capacity. The first 30 miles. through the industrial suburbs of Delhi, are stop-and-go traffic. The Maruti-Suzuki car factories and Hero-Honda motorcycle factories and their parasitic ecosystem for auto jug manufactures ring the … Continue reading “India’s Innovation Front Lines 2009 (Part 1): Of “Jugaar” and A Quick Recovery from Global Recession”
Microsoft’s Director of Environmental Sustainability Talks Green Initiatives, Copenhagen Summit
In the past, Microsoft has had a reputation for being slow moving in the areas of green technology and energy-saving innovation. However, in the last two years, the corporation seems to have turned the tide, stepping up to the sustainability plate and implementing a number of company-wide green initiatives. First, it hired Rob Bernard as … Continue reading “Microsoft’s Director of Environmental Sustainability Talks Green Initiatives, Copenhagen Summit”
Top Five Tech Advances of the 2000s
[Editor’s Note: As the decade comes to an end, we’ve asked Xconomists and other technology leaders around the country to identify the top innovations they’ve seen in their fields the past 10 years, or predict the top disruptive technologies that will impact the next decade.] 1—Digital camera proliferation. Digital cameras and camera phones have become … Continue reading “Top Five Tech Advances of the 2000s”
Melodeo Spoofs Apple-IBM Ad, Welcomes Steve Jobs to the Cloud
Anyone else out there remember the famous 1981 ad by Apple in the Wall Street Journal, welcoming competitor IBM into the personal computer age? The ad was Apple’s stake in the ground, saying it had invented the first PC system—and predicting massive growth and competition in the burgeoning industry. The rest, as they say, is … Continue reading “Melodeo Spoofs Apple-IBM Ad, Welcomes Steve Jobs to the Cloud”
Cell Therapeutics Dangles New Bonuses to Execs for Pixantrone Approval, Boosting Stock
Cell Therapeutics has survived a near-death experience this year, and now it is dishing out a new batch of potentially rich rewards for management to stick around at least two more years. The Seattle-based biotech company (NASDAQ: [[ticker:CTIC]]) said today in a regulatory filing that the board’s compensation committee has approved a new series of … Continue reading “Cell Therapeutics Dangles New Bonuses to Execs for Pixantrone Approval, Boosting Stock”
Report: Security Breach Behind Twitter Outage Did Not Originate with New Hampshire DNS Provider
A hacker attack on the domain name system (DNS) servers that enable access to Twitter’s website disrupted service for many users late Thursday, directing them instead to a web page declaring “This site has been hacked by Iranian Cyber Army.” In the wake of the attack, which was fended off within hours, many fingers are … Continue reading “Report: Security Breach Behind Twitter Outage Did Not Originate with New Hampshire DNS Provider”
Oneforty Raises $1.2M More to Develop Twitter App Store
Oneforty, the Brighton, MA-based Twitter app store startup that has wooed and wowed angel investors on both coasts, has taken in about $1.25 million in new funding, to go along with $372,525 it had previously raised from debt financing that was converted to equity, according to an SEC filing today. The filing indicates the total … Continue reading “Oneforty Raises $1.2M More to Develop Twitter App Store”
TechStars in Seattle Will Be “Centralizing Force” for Entrepreneurs and Startups, Investors Say
Not to hype this too much, but TechStars coming to town could be the rallying point for a new generation of high-tech entrepreneurship in Seattle—the likes of which we haven’t seen before. At least, that’s the word from two of the main investors responsible for bringing the tech startup program here. (By now, most of … Continue reading “TechStars in Seattle Will Be “Centralizing Force” for Entrepreneurs and Startups, Investors Say”
Ambit Nabs Partnership With Astellas, $40M Upfront Cash, To Develop Leukemia Drug
Ambit Biosciences is showing that its third try to build a company looks like a charm. The San Diego-based biotech company said today it has secured a partnership with Japan-based Astellas Pharma to co-develop new drugs for cancer and other diseases. The deal revolves around Ambit’s lead experimental drug for acute myeloid leukemia, AC220, and … Continue reading “Ambit Nabs Partnership With Astellas, $40M Upfront Cash, To Develop Leukemia Drug”
Chu Singles Out FloDesign’s Efficient Wind Turbines at Climate Change Conference
[Editor’s Note: Erik Mellgren, a noted Swedish business and technology journalist who worked with Xconomy as an Innovation Fellow in 2008, sends this article from Stockholm, just as the United Nations climate change conference is winding down in nearby Copenhagen, Denmark.] Massachusetts startup FloDesign Wind Turbine was singled out by U.S. Energy Secretary Steven Chu … Continue reading “Chu Singles Out FloDesign’s Efficient Wind Turbines at Climate Change Conference”
The Decade’s Most Important Biomedical Discovery
The past decade has been rich in biological and biomedical advances. The decade opened with the reports of the large number of new genes within the human genome that encode small non-coding RNAs, or microRNAs. We have learned that these RNAs a) control at least half of all genes, b) are dysfunctional in many cancers … Continue reading “The Decade’s Most Important Biomedical Discovery”
Apple Vs. Google, Genome Sequencing Goes Commercial, and More OVP Predictions for 2010
All this week, the venture capitalists over at OVP Venture Partners in Kirkland, WA, have been posting their thoughts on 2009—such as the biggest surprises in tech and life sciences—as well as their predictions for 2010. It’s a common theme these days, sure, but it’s always fun to get VCs on the record about such … Continue reading “Apple Vs. Google, Genome Sequencing Goes Commercial, and More OVP Predictions for 2010”
As Wireless Industry Moves From Voice to Data, Qualcomm’s Top Execs Discuss Their ‘Big Bets’ on Next-Generation Technologies
Qualcomm CEO Paul Jacobs seemed upbeat, at times even jocular, during a town hall forum at the wireless giant’s corporate headquarters Wednesday night. Perhaps his good humor stemmed from the kickoff question from moderator Brian Modoff, the Deutsche Bank Securities analyst, who asked Jacobs how he views Qualcomm now that the company has entered a … Continue reading “As Wireless Industry Moves From Voice to Data, Qualcomm’s Top Execs Discuss Their ‘Big Bets’ on Next-Generation Technologies”
Aveo Aims for $86M Debut, Exagrid Snags $16M, PatientKeeper Adds $13M, & More Boston-Area Deals News
In honor of the eighth day of Hanukah, here are the top eight deals of the last week. —Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:[[ticker:CBST]]) inked a deal to acquire San Diego-based Calixa Therapeutics for $92.5 million upfront, with as much as $310 million more in potential payments also on the table. The merger of the firms, … Continue reading “Aveo Aims for $86M Debut, Exagrid Snags $16M, PatientKeeper Adds $13M, & More Boston-Area Deals News”
Digital Magazines Emerge—But Glossy Paper Publishers Haven’t Turned the Page on the Past
With all the drama this year around newspapers, including the Boston Globe‘s near-death experience and the actual demise of several other papers such as the Seattle P-I and the Rocky Mountain News, there’s been slightly less hoopla over the fate of magazines. They’re dealing with many of the same problems as newspapers, including a falloff … Continue reading “Digital Magazines Emerge—But Glossy Paper Publishers Haven’t Turned the Page on the Past”
Biogen Idec Bid for Facet Biotech Shot Down, But the Show’s Not Over
[Update: 5:26 pm Eastern, 12/17/09] Biogen Idec failed to persuade shareholders to approve its $450 million hostile takeover bid for Redwood City, CA-based Facet Biotech, but a statement today suggests that this particular corporate dance isn’t over yet. Shareholders of Facet (NASDAQ: [[ticker:FACT]]) turned down Cambridge, MA-based Biogen’s offer of $17.50, and now that the … Continue reading “Biogen Idec Bid for Facet Biotech Shot Down, But the Show’s Not Over”
TechStars Expansion to Seattle Fueled by Boston Success, Says Brad Feld
Yesterday’s official announcement that TechStars, the startup boot camp and seed-stage investment fund, is coming to Seattle next fall has a lot of us here buzzing with anticipation. Founded in Boulder, CO, in 2007, the program invites about 10 small tech startups for three months of training and mentorship, and awards $6,000 per founder in … Continue reading “TechStars Expansion to Seattle Fueled by Boston Success, Says Brad Feld”
Assay Depot Founders Morphed Their Biotech Startup Into e-Commerce Provider of Drug Discovery Services
The three co-founders of San Diego’s Assay Depot started the company in 2006 as a for-hire cancer research outfit, with the big idea of creating a Web-based system that would make it super easy for biomedical researchers to order assays, screening tests, and other lab services. “We were building the website and we really wanted … Continue reading “Assay Depot Founders Morphed Their Biotech Startup Into e-Commerce Provider of Drug Discovery Services”
Crispy Gamer Absorbs Cambridge’s GamerDNA
New York-based Crispy Gamer, an online video game review site, has acquired GamerDNA of Cambridge, MA, which attempted to build a community website that used real-time game play information to generate video game recommendations for community members. Jon Radoff, the founder of GamerDNA, announced the merger in a blog post today. The transition isn’t a … Continue reading “Crispy Gamer Absorbs Cambridge’s GamerDNA”
Calixa Gets Acquired, Pfēnex signs Merck to Licensing Deal, Local Biotechs Report From Breast Cancer Symposium, & More San Diego Life Sciences News
San Diego’s Calixa Therapeutics will be celebrating the holidays in style, after getting acquired by a Massachusetts-based company in the biggest deal of the week. Start your countdown to Christmas here with a rundown of the latest biotech news. —Lexington, MA-based Cubist Pharmaceuticals (NASDAQ: [[ticker:CBST]]) completed its $92.5-million buyout of San Diego antibiotic drug developer … Continue reading “Calixa Gets Acquired, Pfēnex signs Merck to Licensing Deal, Local Biotechs Report From Breast Cancer Symposium, & More San Diego Life Sciences News”
Sequenom Down Syndrome Results “Deliberately Doctored,” Says Partner Xenomics
Sequenom has maintained for months that it “mishandled” clinical test results of a noninvasive prenatal test for Down syndrome, but one of its partners is now accusing the company of committing fraud by having “deliberately doctored” the data. New York-based Xenomics said in October that it is suing San Diego-based Sequenom (NASDAQ: [[ticker:SQNM]]), for as … Continue reading “Sequenom Down Syndrome Results “Deliberately Doctored,” Says Partner Xenomics”
Aveo Pharmaceuticals Eyes $86.3M IPO
Aveo Pharmaceuticals indicated late yesterday that it wants to take the plunge into the public markets, filing papers with the SEC to raise up to $86.25 million in an initial public offering. It’s a brave move, considering that public markets have been stingy to biotech firms seeking IPOs in recent years. The Cambridge, MA-based company … Continue reading “Aveo Pharmaceuticals Eyes $86.3M IPO”
Adimab Proves Fast Antibody Discovery Tool to Merck, Roche; Snags New Deal With Pfizer
Adimab has an audacious goal for speeding up the way antibody drugs are discovered, and apparently it’s delivering the goods. The Lebanon, NH-based biotech company is announcing today it has collected milestone payments from its first two corporate partners, Merck and Roche, and built on that experience to grab a pair of additional partnerships with … Continue reading “Adimab Proves Fast Antibody Discovery Tool to Merck, Roche; Snags New Deal With Pfizer”
Anadys Hepatitis C Drug Shows Early Sign of Viral-Killing Punch, Without Dreaded Rash
Anadys Pharmaceuticals has bet the company on its experimental drug for hepatitis C, and an early peek at clinical trial results show the San Diego company is still in the game. Anadys (NASDAQ: [[ticker:ANDS]]) is announcing today it has captured data from the first 44 patients who were randomly assigned to get a low dose … Continue reading “Anadys Hepatitis C Drug Shows Early Sign of Viral-Killing Punch, Without Dreaded Rash”
Zulily Zips Out of Stealth and Raises $4.6M, Led by Maveron and Ex-Blue Nilers
I’m no expert in online retail, but this seems pretty interesting. Seattle-based Zulily has emerged from stealth mode and is announcing today a $4.6 million Series A funding round led by Maveron, the Seattle venture capital firm founded by Howard Schultz and Dan Levitan. Maveron is known for its investments in consumer and tech businesses … Continue reading “Zulily Zips Out of Stealth and Raises $4.6M, Led by Maveron and Ex-Blue Nilers”
Chicken Little is History, Now It’s Time for Old School VC
“Biotech is Broken!” “Pharmaceuticals Out of Balance!” “Venture Capital abandoning Biotech Sector!” Lately articles on the state of biotech scream out like spinning headlines on the MovieTone News Reels from seventy years ago: “Millions out of work!” or “War in the Pacific!” Since I’m penning my article on Pearl Harbor Day, the dramatic headlines pop … Continue reading “Chicken Little is History, Now It’s Time for Old School VC”
Dendreon Nails Down $409M, Stewart Parker Gets Itch to Return, Seattle Genetics Finds New Partner, & More Seattle-Area Life Sciences News
‘Tis apparently the season to cram in as much biotech news as possible before taking a holiday breather. —Dendreon (NASDAQ: [[ticker:DNDN]]) snapped up a total of $409 million through a stock offering. The Seattle-based biotech company sold 15 million shares in an initial piece of the financing that brought in $356 million, and secured the … Continue reading “Dendreon Nails Down $409M, Stewart Parker Gets Itch to Return, Seattle Genetics Finds New Partner, & More Seattle-Area Life Sciences News”
Invent a Cool Clothing Site, Now Leave the Country—Fan Bi, Blank Label, and The Case for the “Founders Visa”
Twenty-two-year-old Fan Bi is the mastermind behind Blank Label, an online clothier where fashion-conscious young men can use sophisticated “configurator” software to design their own dress shirts from a variety of fabrics and collar, cuff, and pocket styles. Tailors in Shanghai assemble shirts from the designs and ship the finished articles back to the U.S., … Continue reading “Invent a Cool Clothing Site, Now Leave the Country—Fan Bi, Blank Label, and The Case for the “Founders Visa””
TechStars, the Startup Boot Camp, Coming to Seattle Next Fall, Led by Andy Sack
Yes, it’s another big rumor confirmed today… TechStars, the two-year-old seed-stage investment fund and boot camp for tech startups, announced it is expanding to Seattle in the fall of 2010. Seattle entrepreneur and investor Andy Sack will lead the local effort as executive director. Sack has previously served as a mentor in Boston and in … Continue reading “TechStars, the Startup Boot Camp, Coming to Seattle Next Fall, Led by Andy Sack”
Ontela Merges with Newly Independent Photobucket, Looks to Combine Companies’ Reach on Web and Mobile
OK, so there was truth to the rumors. But this is no ordinary merger or acquisition. Seattle-based Ontela, the mobile imaging startup focused on getting pictures off your camera phone, announced today it is merging operations with Photobucket, the Denver, CO-based photo sharing site. Financial details of the merger weren’t announced. The new, combined entity … Continue reading “Ontela Merges with Newly Independent Photobucket, Looks to Combine Companies’ Reach on Web and Mobile”
Acceleron Pharma Reports $10.9M Financing
Acceleron Pharma, the Cambridge, MA-based developer of biotech drugs for anemia, bone loss, and other ailments, reports in an SEC filing that it has raised $10.9 million in equity financing. The funding includes an $8 million investment that Cambridge-based biotech Alkermes (NASDAQ:[[ticker:ALKS]])made as part of a licensing deal Luke reported early this month, as well … Continue reading “Acceleron Pharma Reports $10.9M Financing”
Biogen Idec Board in Flux, Cubist Acquires Calixa, ImmunoGen Drug Passes Clinical Test, & More Boston-Area Life Sciences News
Gadzooks, was this a busy news week for the biotech, devices, and healthcare IT sectors in New England. Here’s the lightning round version: —Luke examined Cambridge, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]])’s efforts to create antibody drugs that can hit two targets at once. —Cambridge-based Parasol Therapeutics, an MIT spinoff developing treatments and diagnostics for influenza … Continue reading “Biogen Idec Board in Flux, Cubist Acquires Calixa, ImmunoGen Drug Passes Clinical Test, & More Boston-Area Life Sciences News”
ULocate’s Where Is That Rare Beast: A Location-Based Mobile Platform Earning Real Money
As the news cycle slows down with the approach of the holidays, I’ve had a bit of time to attend to my towering backlog of unpublished interviews, including the one below, from a visit to Boston-based uLocate. CEO Walt Doyle and vice president of marketing Dan Gilmartin had me over on November 9 for the … Continue reading “ULocate’s Where Is That Rare Beast: A Location-Based Mobile Platform Earning Real Money”
Cool Device from San Diego’s BeneChill May Improve Odds for Cardiac Arrest Victims
Research over the last several years has shown that lowering the temperatures of unconscious cardiac arrest patients improves their odds of survival without brain damage. This intervention commonly begins in the hospital because most temperature-lowering technologies (water-filled blankets, blood-cooling machines) are not suited for use by ambulance crews. San Diego-based BeneChill wants to put temperature-lowering … Continue reading “Cool Device from San Diego’s BeneChill May Improve Odds for Cardiac Arrest Victims”
Google Senior Exec Alan Eustace on Innovation Strategy and the Technology of the Next Decade
If ever a company defied hyperlocal coverage, it’s Google. Whether you live in Boston or Bosnia, Seattle or Shanghai, Google is a big deal—and it’s getting bigger every day. Whether it’s attracting or gobbling up the best companies and talent in New England or Southern California, or competing with giants like Microsoft (Bing) and Amazon … Continue reading “Google Senior Exec Alan Eustace on Innovation Strategy and the Technology of the Next Decade”
Advanced Cell Technology Betting Future on Embryonic Stem Cell Therapy for Eye Disease
Advanced Cell Technology is banking on an experimental cellular therapy for a rare eye disease to show the world that controversial embryonic stem cells have a place in treating diseases. Amid serious financial constraints at the Worcester, MA-based biotech firm (OTCBB[[ticker:ACTC]]), a plan is in place to pioneer the use of cellular therapies made with … Continue reading “Advanced Cell Technology Betting Future on Embryonic Stem Cell Therapy for Eye Disease”
Xconomy Forum: The Biotech Odyssey and Xconomy’s Ode to Innovation and Clean Air
Leave it to the Greeks to provide an epic mythology for interpreting the essence of biotech innovation. As John Maraganore of Cambridge, MA-based Alnylam Pharmaceuticals puts it, drug development is a voyage of Odysseus that requires wily and ingenious problem-solving and extraordinary seamanship. Put another way by Kleanthis Xanthopoulos of Carlsbad, CA-based Regulus Therapeutics, the … Continue reading “Xconomy Forum: The Biotech Odyssey and Xconomy’s Ode to Innovation and Clean Air”